Investigator Studies Program (MISP): Pediatric Hexavalent
Effective January 2021, the Investigator Studies Program Review Committee (MISP-RC) for the Pediatric Hexavalent Vaccine will accept proposals within our current areas of interest (AOI) up to July 2, 2021. This is a competitive review process that will be conducted in August 2021 by the MISP Review Committee. Decisions will be made on the basis of scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.

The following areas are of interest to the Investigator Studies Program Committee:

  • Studies of the practical use and administration of a pediatric hexavalent vaccine in various healthcare settings (such as, but not limited to, compliance, timeliness and quality measures)
  • Studies of pediatric hexavalent vaccine in special populations where limited data exist, and where there is not a contraindication to vaccination
  • Data evaluating disease control after the administration of pediatric hexavalent vaccine

Please complete a protocol with detailed budget via Visiontracker, the Company's on-line study management system (in US). The proposals will be collectively reviewed and selected by the MISP Committee.

Critical Activities and Timelines:
Activity 1st Review Cycle
Protocol Submission with CV and Detailed Budget July 2, 2021
Target Review Committee Meeting Date August 2021
Target Final Comments to Investigator September 2021


MISP Information
This site is intended for US investigators only. Investigators outside of the US interested in submitting research proposals to the Investigator Studies Program should contact their local MSD office.